Cohere Medicare Advantage Policy - Computed Tomography (CT), Colonography

Clinical Policy for Medical Necessity Review

Version: 2
Cohere Health UMC Approval Date: October 23, 2025
Last Annual Review: October 23, 2025
Revision: Not Applicable
Next Annual Review: October 23, 2026

Important Notices

Notices & Disclaimers:

GUIDELINES ARE SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION-MAKING OF END USERS.

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine the medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third-party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision-making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice. This policy may be superseded by existing and applicable Centers for Medicare & Medicaid Services (CMS) statutes.

Other Notices:

Policy Information:

Specialty Area: Diagnostic Imaging
Policy Name: Cohere Medicare Advantage Policy - Computed Tomography (CT), Colonography
Type: [**X**] Adult (18+ yo) | [**X**] Pediatric (0-17 yo)

Table of Contents

Important Notices **2**
Medical Necessity Criteria **4**
Service: Computed Tomography (CT), Colonography **4**
Related CMS Documents 4
Description 4
Medical Necessity Criteria 5
Indications 5
Non-Indications 7
Definitions 8
Disclaimer on Radiation Exposure in Pediatric Populations 8
Level of Care Criteria 9
Procedure Codes (CPT/HCPCS) 10
Evaluation of Clinical Harms and Benefits 11
Medical Evidence **13**
References **15**
Policy Revision History/Information **19**

Medical Necessity Criteria

Service: Computed Tomography (CT), Colonography

Related CMS Documents

Please refer to the CMS Medicare Coverage Database for the most current applicable CMS National Coverage.[1-3]

- CMS Manual System. Pub 100-20 One-Time Notification. March 20, 2025.
- National Coverage Determination (NCD). Colorectal cancer screening tests (210.3).
- National Coverage Determination (NCD). Computed tomography (220.1).

Description

Computed tomography (CT) colonography (also known as virtual colonoscopy) is a diagnostic imaging procedure that uses detailed images of the colon and rectum. The procedure typically begins with bowel preparation to cleanse the colon, followed by the insertion of a small tube into the rectum to gently inflate the colon with air or carbon dioxide. Images are obtained while the patient lies in different positions on the CT scanner, such as on the back and stomach. Specialized software reconstructs the CT images into a two- or three-dimensional view of the colon's interior, allowing visualization of the mucosal surface and detection of abnormalities such as polyps or masses.[4] The procedure should be conducted in a facility compliant with the standards of the American College of Radiology (ACR), and performed by a physician trained in CT colonography.[5]

Medical Necessity Criteria

Indications

Computed Tomography (CT), Colonography is considered appropriate if **ANY** of the following is **TRUE**:

- The procedure is a screening for colorectal cancer, and **ALL** of the following[1]:
  - **ANY** of the following:
    - The patient is at average risk for colorectal cancer, and **ALL** of the following:
      - The patient is 45-85 years of age[6]; **AND**
      - The patient has no personal history of colorectal predisposing conditions (e.g., colorectal cancer, adenomatous polyps, inflammatory bowel disease); **AND**
      - The patient has no known family history of colorectal cancer or advanced adenoma in a first-degree relative; **OR**
    - The patient is at moderate or increased risk for colorectal cancer, and **ALL** of the following[7]:
      - **ANY** of the following:
        - The patient has one first-degree relative with colorectal cancer or an advanced adenoma diagnosed before age 60; **OR**
        - The patient has two or more first-degree relatives with colorectal cancer or advanced adenoma at any age; **AND**
      - **ANY** of the following:
        - The patient is no more than 10 years younger than the age of the youngest affected relative at their diagnosis; **OR**
        - The patient is greater than or equal to 40 years of age; **AND**
  - **ANY** of the following:
    - The procedure is an initial screening; **OR**
    - The patient had a prior CT colonography at least 5 years ago[8,9]; **OR**
- Post-surgical follow-up of a patient for a colonic stoma or after a colectomy[5]; **OR**
- Before colorectal cancer surgery for the identification of the tumor or to search for synchronous lesions[5]; **OR**
- **ALL** of the following:

- Colonoscopy is contraindicated or incomplete due to **ANY** of the following reasons:
  - Prior optical colonoscopy was incomplete due to **ANY** of the following[5,8]:
    - An obstructing neoplasm; **OR**
    - Intrinsic scarring; **OR**
    - Stricture; **OR**
    - Redundant or tortuous colon; **OR**
    - Spasm; **OR**
    - Obstruction from prior surgery, radiation, or diverticular disease; **OR**
    - Extrinsic compression; **OR**
  - The patient is at increased risk for complications during an optical colonoscopy due to **ANY** of the following[5]:
    - Anticoagulant use that cannot be safely reversed before the procedure; **OR**
    - Coagulopathy; **OR**
    - Complications from prior optical colonoscopy; **OR**
    - Increased risk of bowel perforation; **OR**
    - Sedation risk as indicated by an American Association of Anesthesiologists (ASA) Physical Status classification of IV or above[10]; **OR**
    - The patient is 76 to 85 years of age, and medical necessity is determined based on symptoms or risk factors[11]; **AND**
- **ANY** of the following:
  - Evaluation of a submucosal abnormality detected on colonoscopy or another imaging study; **OR**
  - The procedure is for surveillance in moderate and high-risk individuals as defined by **ALL** of the following:
    - Documented discussion with the patient that optical colonoscopy is considered the gold standard in this setting; **AND**
    - **ANY** of the following:
      - Biopsy-proven precancerous polyps on prior colonoscopy; **OR**
      - Prior therapeutic abdominal or pelvic radiation - every 5 years beginning at age 35 for at-risk survivors or 10 years after the completion of radiotherapy (whichever occurs last)[12]; **OR**
  - The procedure is a diagnostic examination in symptomatic patients with **ALL** of the following[5]:

        - Documented discussion with the patient that optical colonoscopy is considered the gold standard in this setting; **AND**
        - The patient has signs or symptoms suggesting colorectal cancer, including **ANY** of the following[5]:
            - The positive test result indicates a relative elevation in risk (e.g., positive fecal immunochemical test, positive fecal occult blood test [FOBT], positive mt-sDNA); **OR**
            - Iron-deficiency anemia; **OR**
            - Weight loss; **OR**
            - Hematochezia (Blood in stool); **OR**
- Repeat imaging (defined as a repeat request following recent imaging of the same anatomic region with the same or similar modality) will be considered reasonable and necessary if **ALL** the following are **TRUE**:
    - There are no established guidelines; **AND**
    - **ANY** of the following:
        - There are new or worsening symptoms not addressed in the guidelines, such that repeat imaging would influence treatment; **OR**
        - There is a need for a one-time clarifying follow-up of a prior indeterminate finding; **OR**
        - In the absence of change in symptoms, there is an established need for monitoring which would influence management.

Non-Indications

Computed Tomography (CT), Colonography is not considered appropriate if **ANY** of the following is **TRUE**:

- The patient has undergone advanced imaging of the same body part within 3 months without undergoing treatment or developing new or worsening symptoms[13]; **OR**
- Attempted colonoscopy within 48 hours; **OR**
- Known or suspected current colon perforation[5,14] **OR**
- Routine follow-up of inflammatory bowel disease[5,14]; **OR**
- Hereditary polyposis or Lynch syndromes[5,14]; **OR**
- Evaluation of anal canal disease (e.g., perianal fissure).[5,14]

*NOTE: CT Colonography should not be performed if the patient has symptomatic acute conditions such as colitis, diarrhea, recent acute diverticulitis, abdominal wall hernia, history of recent colorectal surgery, high-grade or symptomatic small bowel obstruction, or history of recent colonoscopic biopsy, polypectomy. The imaging center and the ordering provider should consider these conditions prior to ordering a CT colonography.[5,14]
**NOTE: The referring professional and radiologist should discuss the risks and benefits of contrast media administration, including possible prophylaxis, in patients with chronic or worsening kidney disease or severe renal failure.
***NOTE: CT in patients with claustrophobia should be requested at the discretion of the ordering provider.
****NOTE: CT in pregnant patients should be requested at the discretion of the ordering provider and obstetric care provider.

Definitions

- **First-degree relative:** A relative who shares approximately 50% of your genes (e.g., a parent, sibling, or child).[7]
- **Second-degree relative:** A relative who shares approximately 25% of your genes (e.g., a grandparent, grandchild, aunt, uncle, niece, nephew, or half-sibling).[7]
- **Average risk:** Individuals with no personal history of colorectal cancer, adenomatous polyps, inflammatory bowel disease, hereditary colorectal syndromes, other colorectal predisposing conditions, or first-degree relative family history of colorectal cancer.[7,9]
- **Moderate or increased risk:** Individuals with one first-degree relative with colorectal cancer or an advanced adenoma diagnosed before age 60, or two or more first-degree relatives with colorectal cancer or adenomatous polyps at any age.[7,9]
- **High-risk:** Individuals with a hereditary colorectal cancer syndrome (such as Lynch syndrome, familial adenomatous polyposis, or hereditary polyposis or nonpolyposis), or with long-standing inflammatory bowel disease involving the colon.[7,9]

Disclaimer on Radiation Exposure in Pediatric Populations

Due to the heightened sensitivity of pediatric patients to ionizing radiation, minimizing exposure is paramount. At Cohere, we are dedicated to ensuring that every patient, including the pediatric population, has access to

appropriate imaging following accepted guidelines. Radiation risk is dependent mainly on the patient's age at exposure, the organs exposed, and the patient's sex, though there are other variables. The following technical guidelines are provided to ensure safe and effective imaging practices:

Radiation Dose Optimization: Adhere to the lowest effective dose principle for pediatric imaging. Ensure that imaging protocols are specifically tailored for pediatric patients to limit radiation exposure.[15,16]

Alternative Modalities: Prioritize non-ionizing imaging options such as ultrasound or MRI when clinically feasible, as they are less likely to expose the patient to ionizing radiation. For instance, MRI or ultrasound should be considered if they are more likely to provide an accurate diagnosis than CT, fluoroscopy, or radiography.[15,16]

Cumulative Dose Monitoring: Implement systems to track cumulative radiation exposure in pediatric patients, particularly for those requiring multiple imaging studies. Regularly reassess the necessity of repeat imaging based on clinical evaluation.[15,16]

CT Imaging Considerations: When CT is deemed the best method for achieving a correct diagnosis, use the lowest possible radiation dose that still yields reliable diagnostic images.[15,16]

Cohere Imaging Gently Guideline
The purpose of this guideline is to act as a potential override when clinically indicated to adhere to Imaging Gently and Imaging Wisely guidelines and As Low As Reasonably Possible (ALARA) principles.[15,16]

Level of Care Criteria

Inpatient or Outpatient

Procedure Codes (CPT/HCPCS)

CPT/HCPCS Code	Code Description
74261	Computed tomography (CT) colonography, diagnostic; without contrast material, with image post-processing
74262	Computed tomography (CT) colonography, diagnostic; with contrast material and non-contrast images, with image post-processing
74263	Computed tomographic (CT) colonography, screening, including image postprocessing
76380	Computed tomography, limited or localized follow-up study

Disclaimer: S Codes are non-covered per CMS guidelines due to their experimental or investigational nature.

Evaluation of Clinical Harms and Benefits

Clinical determinations for Medicare Advantage beneficiaries are made in accordance with 42 CFR 422.101 guidance outlining CMS's required approach to decision hierarchy in the setting of NCDs/LCDs identified as being "not fully established". When clinical coverage criteria are "not fully established" Medicare Advantage organizations are instructed to create publicly accessible clinical coverage criteria based on widely-accepted clinical guidelines and/or scientific studies backed by a robust clinical evidence base. Clinical coverage criteria provided by Cohere Health in this manner include coverage rationale and risk/benefit analysis.

The potential clinical harms of using these criteria for Computed Tomography (CT), Colonography may include:

- Adverse effects of delayed or denied detection of cancer or precancerous polyps, including disease progression and increased mortality.[17]
- Inherent imaging risks, including cumulative radiation exposure, contrast, allergy, nephrotoxicity, and contrast extravasation into surrounding tissues.[15,18-20]
- Potential danger during pregnancy. CT imaging completed during pregnancy confers a dose of ionizing radiation to the fetus and is generally only utilized when the potential benefits of this specific imaging modality outweigh the risks to the pregnancy.[21] Fetal risk includes fetal demise, intrauterine growth restriction, microcephaly, delayed intellectual development, risk of childhood cancer, and fetal thyroid injury.[21]
- CT colonography is contraindicated for patients with active colonic inflammation, due to a high risk of bowel perforation.[22]
- Increased healthcare costs and complications from the inappropriate use of additional interventions.[23]

The clinical benefits of using these criteria for Computed Tomography (CT), Colonography may include:

- Improved patient selection for this effective and minimally invasive imaging modality to detect colorectal cancer.[5]
- CT Colonoscopy, unlike stool-based cancer screening tests, can detect precancerous polyps before they become cancerous, and may allow endoscopic evaluations to be conducted on the same day, if necessary.[5,24]

- Compared to instrument colonoscopy, CT colonography has a lower risk of complications. Furthermore, CT colonography does not require sedation and is relatively safe for individuals with medical comorbidities that preclude colonoscopy.[24]
- CT colonography requires less frequent testing than stool-based screening test.[24]
- Enhanced overall patient satisfaction and healthcare experience.

Medical Evidence

Sakai et al. (2023) compared the accuracy and sensitivity of three methods for detecting colorectal polyps: CT colonography, optical colonoscopy, and colon endoscope capsule. Optical colonoscopy detected a total of 36 polyps in the 21-patient cohort. In contrast, CT colonography detected only 11 polyps. Further analysis revealed that this difference was driven by differences in the detection of polyps less than 6 mm: optical colonoscopy detected 27 of these smaller polyps while CT colonography failed to detect any. Despite these differences, the authors noted that all three evaluated methods were well-tolerated by all patients and concluded that patient preference, study availability, and contraindications should guide study selection.[25]

Jain et al. (2022) outline the updated colorectal cancer (CRC) screening strategies recommended by the United States Preventive Services Task Force (USPSTF) in 2021. Average-risk individuals should start screening at age 45. The Task Force suggests several screening methods: high-sensitivity guaiac fecal occult blood test (HSgFOBT), fecal immunochemical test (FIT), multi-target stool DNA (mt-sDNA) test, computed tomographic (CT) colonography (virtual colonoscopy), flexible sigmoidoscopy, flexible sigmoidoscopy with FIT, or traditional colonoscopy. Numerous emerging and innovative screening approaches are being researched and are on the horizon for primary screening in average-risk individuals. These include blood-based screening or "liquid biopsy," colon capsule endoscopy, urinary metabolomics, and stool-based microbiome testing to detect colorectal polyps or CRC. Compared to traditional colonoscopy, the advantages of CT colonography include a lower risk of complications, less invasive, sedation not required, and the clinician being able to visualize the entire colon. In addition, CT colonography requires a less frequent testing interval than stool-based modalities and is relatively safe for individuals with medical comorbidities that preclude colonoscopy. Same-day endoscopic evaluation may also be performed if indicated.[24]

Gupta et al. (2022) review CRC screening for identifying polyps and cancer within the colon. The sensitivity for detecting lesions greater than or equal to 1 cm varies between 67 and 94%, while specificity ranges from 86 to 98%.

Notably, an estimated incidence of potentially significant extracolonic findings necessitating further investigation, ranging from 3.4–26.9%, with 1.3–11.4% possibly requiring follow-up due to incomplete characterization. Several studies have shown superior sensitivity in detecting colorectal cancer compared to colonoscopy, mainly when the endoscopist is unaware of CT colonography results. Repeat screening every 5 years is recommended by the USPSTF.[26]

Shaukat et al. (2022) discuss CT colonography to facilitate the identification and pinpointing of polyps and cancers within the colon through a reconstructed 3D or 4D visualization. Two extensive trials have evaluated the diagnostic efficacy of CT colonography against optical colonoscopy conducted on the same day. One study involving 1233 individuals at average risk showcased CT colonography's test characteristics, revealing 92% sensitivity and 96% specificity for adenomas measuring 10mm or larger as detected by optical colonoscopy. Additionally, it demonstrated 86% sensitivity and 80% specificity for adenomas measuring 6mm or larger. The National CT Colonography Trial (NCTC), sponsored by the American College of Radiology Imaging Network (ACRIN), comprised 2600 asymptomatic participants undergoing same-day CT colonography and optical colonoscopy. Results revealed a sensitivity of 84% for adenomas or colorectal cancer (CRC) measuring 10mm or larger, with a specificity of 85%. Furthermore, a sensitivity of 70% was observed for adenomas measuring 6mm or larger, with a specificity of 86%. A notable critique of CT colonography is the failure to report lesions smaller than 6mm, the clinical significance of which remains uncertain.[27]

References

1. Centers for Medicare & Medicaid Services (CMS). CMS Manual System. Pub 100-20 One-Time Notification. Transmittal 13097. Published March 20, 2025. https://www.cms.gov/files/document/r13097otn.pdf
2. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD). Colorectal cancer screening tests (210.3). Published January 1, 2023. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=281&ncdver=7&bc=
3. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD). Computed tomography (220.1). Published March 12, 2008. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=176&ncdver=2&bc=0
4. Cotton PB, Durkalski VL, Pineau BC, et al. Computed tomographic colonography (virtual colonoscopy): A multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. *JAMA*. 2004;291(14):1713-1719. doi:10.1001/jama.291.14.1713
5. American College of Radiology (ACR), Society of Abdominal Radiology (SAR), Society of Computed Body Tomography (SCBT). ACR–SAR–SCBT-MR practice parameter for the performance of computed tomography (CT) colonography in adults. Resolution 4. Updated 2024. https://gravitas.acr.org/PPTS/GetDocumentView?docId=33
6. US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. *JAMA*. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238
7. Issaka RB, Chan AT, Gupta S. AGA clinical practice update on risk stratification for colorectal cancer screening and post-polypectomy surveillance: Expert review. *Gastroenterology*. 2023;165(5):1280-1291. doi:10.1053/j.gastro.2023.06.033

8. Moreno C, Kim DH, et al. ACR appropriateness criteria. Colorectal cancer screening. *J Am Coll Radiol*. 2018 May;15(5S):S56-S68. doi:10.1016/j.jacr.2018.03.014
9. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines: Colorectal cancer screening (ver. 2.2025). Published June 24, 2025. https://www.nccn.org/
10. American Society of Anesthesiologists (ASA). Standards and parameters: Statement on ASA physical status classification system. Updated December 13, 2020. https://www.asahq.org/standards-and-practice-parameters/statement-on-asa-physical-status-classification-system
11. Gornick D, Kadakuntla A, Trovato A, et al. Practical considerations for colorectal cancer screening in older adults. *World J Gastrointest Oncol*. 2022 Jun 15;14(6):1086-1102. doi:10.4251/wjgo.v14.i6.1086
12. Daniel CL, Kohler CL, Stratton KL, et al. Predictors of colorectal cancer surveillance among survivors of childhood cancer treated with radiation: A report from the childhood cancer survivor study. *Cancer*. 2015 Jun 1;121(11):1856-63. doi:10.1002/cncr.29265
13. Wasser EJ, Prevedello LM, Sodickson A, et al. Impact of a real-time computerized duplicate alert system on the utilization of computed tomography. *JAMA Intern Med*. 2013;173(11):1024-1026. doi:10.1001/jamainternmed.2013.543
14. Cash BD, Rockey DC, Brill JV. AGA standards for gastroenterologists for performing and interpreting diagnostic computed tomography colonography: 2011 update. *Gastroenterology*. 2011 Dec;141(6):2240-66. doi:10.1053/j.gastro.2011.09.043
15. The Image Gently Alliance. Procedures - image gentle and CT scans. Updated 2014. https://www.imagegently.org/Procedures/Computed-Tomography
16. National Cancer Institute. Radiation risks and pediatric computed tomography (CT): A guide for health care. Updated September 4, 2018. https://www.cancer.gov/about-cancer/causes-prevention/risk/radiation/pediatric-ct-scans

17. Flugelman AA, Stein N, Segol O, et al. Delayed colonoscopy following a positive fecal test result and cancer mortality. *JNCI Cancer Spectr.* 2019;3(2):pkz024. Published 2019 May 2. doi:10.1093/jncics/pkz024
18. Zhang F, Lu Z, Wang F. Advances in the pathogenesis and prevention of contrast-induced nephropathy. *Life Sci*. 2020;259:118379. doi:10.1016/j.lfs.2020.118379. PMID: 32890604
19. Rudnick MR, Leonberg-Yoo AK, Litt HI, et al. The controversy of contrast-induced nephropathy with intravenous contrast: What is the risk? *Am J Kidney Dis*. 2020;75(1):105-113. doi:10.1053/j.ajkd.2019.05.022. PMID: 31473019
20. Summers LN, Harry ML, Colling KP. Evaluating our progress with trauma transfer imaging: Repeat CT scans, incomplete imaging, and delayed definitive care. *Emerg Radiol*. 2021;28(5):939-948. doi:10.1007/s10140-021-01938-x. PMID: 34050410
21. Nguyen T, Bhosale PR, Cassia L, et al. Malignancy in pregnancy: Multimodality imaging and treatment. *Cancer*. 2023;129(10):1479-1491. doi:10.1002/cncr.34688. PMID: 36907983
22. Scalise P, Mantarro A, Pancrazi F, et al. Computed tomography colonography for the practicing radiologist: A review of current recommendations on methodology and clinical indications. *World J Radiol*. 2016 May 5;8(5):472. doi: 10.4329/wjr.v8.i5.472. PMID: 27247713
23. Kjelle E, Brandsæter IØ, Andersen ER, et al. Cost of low-value imaging worldwide: A systematic review. *Appl Health Econ Health Policy*. 2024;22(4):485-501. doi:10.1007/s40258-024-00876-2. PMID: 38427217
24. Jain S, Maque J, Galoosian A, et al. Optimal strategies for colorectal cancer screening. *Curr Treat Options Oncol*. 2022 Apr;23(4):474-493. doi: 10.1007/s11864-022-00962-4. PMID: 35316477; PMCID: PMC8989803
25. Sakai CM, Ueda SKN, Caiado AHM, et al. A head-to-head comparison of computed tomography colonography, optical colonoscopy, and colon endoscopic capsule for the detection of polyps after partial colectomy or rectosigmoidectomy for colorectal cancer: A pilot study. *Cureus*. 2023;15(5):e38410. Published 2023 May 1. doi:10.7759/cureus.38410
26. Gupta S. Screening for colorectal cancer. *Hematol Oncol Clin North Am.* 2022 Jun;36(3):393-414. doi:10.1016/j.hoc.2022.02.001

27. Shaukat A, Levin TR. Current and future colorectal cancer screening strategies. *Nat Rev Gastroenterol Hepatol.* 2022 Aug;19(8):521-531. doi:10.1038/s41575-022-00612-y

Policy Revision History/Information

Original Date: October 24, 2024		
Review History		
Version 1.1	05/22/2025	Revision date/version updated. Removed retired CMS LCD bookmarks and references for the following: L34055, Billing and Coding Article A56800, L33562 and Billing and Coding Article A57026, LCD L33452 and Billing and Coding Article A56772. Removed archived and no longer referenced CMS LCDs L34005, L34454, L34614. Added CMS Memo Pub 100-20 from March 2025. Removed non-indication language regarding screening criteria in relation to new guidance from CMS Memo cited above.
Version 2	10/23/2025	Annual review. Removed references to 2 out-of-scope LCDs. Replaced Recommended Clinical Approach with Description. Added indications for screening. Edited surveillance indications for clarity and ease-of-use. Revised repeat imaging indications. Removed non-indications for contrast allergy, colorectal surgery in the last month, polypectomy

		or mucosectomy in the last week, and high-grade or symptomatic bowel obstruction. Expanded notes on conditions wherein CT colonography should not be performed (e.g., abdominal wall hernia) and added note on risks of contrast media. Added definitions section. Expanded harms and benefits and medical evidence sections (2 references).